ImageneBio, Inc. (IMA)
About ImageneBio, Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $800.0K
- Net income
- -$45.3M
- Total assets
- $153.0M
- Market cap
- $63.7M
- Operating margin
- -6056.4%
- Net margin
- -5668.6%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $800.0K
- Operating expenses
- $49.3M
- Operating income
- -$48.5M
- Income tax
- -$350.0K
- Net income
- -$45.3M
- EPS (basic)
- $-9.64
- EPS (diluted)
- $-9.64
Balance sheet
- Total assets
- $153.0M
- Current assets
- $140.3M
- Total liabilities
- $19.8M
- Current liabilities
- $11.2M
- Shareholders’ equity
- $133.1M
Cash flow
- Operating cash flow
- -$47.8M
- Investing cash flow
- -$5.8M
- Financing cash flow
- $135.5M
- Net cash flow
- $82.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $63.7M
- EPS (diluted)
- $-9.64
- Shares outstanding
- 11.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 28, 2025
ImageneBio, Inc. (IMA) Stock Price
- Reported a net loss of $45.3M in FY2025.
- Trading 69% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ImageneBio, Inc..
Write a review
News about ImageneBio, Inc.
News & sentiment via Polygon.io
ImageneBio, Inc.: frequently asked questions
Is ImageneBio, Inc. an American company?
ImageneBio, Inc. is a US-based company headquartered in San Diego, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is ImageneBio, Inc. headquartered?
ImageneBio, Inc. is headquartered in San Diego, California, United States.
Is ImageneBio, Inc. publicly traded?
Yes — ImageneBio, Inc. is a publicly traded company. Its stock trades under the ticker symbol IMA on the NASDAQ.
What does ImageneBio, Inc. do?
ImageneBio, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
